EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY 4.0

Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials

Pajaree Sriuttha iD, Buntitabhon Sirichanchuen, Unchalee Permsuwan

International Journal of Hepatology · 2018 · 2018 · 1-13

DOI: 10.1155/2018/5253623 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Hepatology, 2018. Verfasst von Pajaree Sriuttha und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand. Die Arbeit wurde bisher 120-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most widely used medication in several countries, including Thailand. NSAIDs have been associated with hepatic side effects; however, the frequency of these side effects is uncertain. Aim of the Review . To systematically review published literature on randomized, controlled trials that assessed the risk of clinically significant hepatotoxicity associated with NSAIDs.

Methods

Searches of bibliographic databases EMBASE, PubMed, and the Cochrane Library were conducted up to July 30, 2016, to identify randomized controlled trials of ibuprofen, naproxen, diclofenac, piroxicam, meloxicam, mefenamic acid, indomethacin, celecoxib, and etoricoxib in adults with any disease that provide information on hepatotoxicity outcomes.

Results

Among the 698 studies, 18 studies met the selection criteria. However, only 8 studies regarding three NSAIDs (celecoxib, etoricoxib, and diclofenac) demonstrated clinically significant hepatotoxic evidence based on hepatotoxicity justification criteria. Of all the hepatotoxicity events found from the above-mentioned three NSAIDs, diclofenac had the highest proportion, which ranged from 0.015 to 4.3 (×10 −2 ), followed by celecoxib, which ranged from 0.13 to 0.38 (×10 −2 ), and etoricoxib, which ranged from 0.005 to 0.930 (×10 −2 ).

Conclusion

Diclofenac had higher rates of hepatotoxic evidence compared to other NSAIDs. Hepatotoxic evidence is mostly demonstrated as aminotransferase elevation, while liver-related hospitalization or discontinuation was very low.

Autor:innen und Institutionen

  • Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.

ORCID-Profile: Pajaree Sriuttha

Zitieren

APA

Sriuttha, P., Sirichanchuen, B., & Permsuwan, U. (2018). Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials. International Journal of Hepatology, 2018, 1-13. https://doi.org/10.1155/2018/5253623

Vancouver

Sriuttha P, Sirichanchuen B, Permsuwan U. Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials. International Journal of Hepatology. 2018;2018:1-13. doi:10.1155/2018/5253623

BibTeX
@article{Sriuttha2018,
  author = {Sriuttha, Pajaree and Sirichanchuen, Buntitabhon and Permsuwan, Unchalee},
  title = {Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials},
  journal = {International Journal of Hepatology},
  year = {2018},
  volume = {2018},
  pages = {1--13},
  doi = {10.1155/2018/5253623}
}
Kostenlos starten →